Recent Updates
Recently added Catalysts

Alendronate ,

Phase 1

Healthy | Small molecule | Other |Dr. Reddy's Laboratories Ltd|Last Updated: Jun 14, 2010

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment80
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01133496Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting ConditionsPHASE1 COMPLETED 80Dec 1, 2006Apr 1, 2007Jun 14, 20101 India
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Bioequivalence based on Cmax and AUC parameters
5 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Alendronate SodiumEXPERIMENTALAlendronate Sodium Tablets, 70 mg of Dr. Reddy's
FosamaxACTIVE_COMPARATORFosamax Tablets 70 mg of Merck \& Company. Inc., USA.
Interventions
NameTypeDescription
Alendronate Sodium Tablets, 70 mgDRUGAlendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Healthy human subjects aged between 18 and 45 years (including both). 2. Subjects with a BMI between 18.5 - 24.9 Kg/m2 but weight not less than 45 Kgs. 3. Female subjects who are postmenopausal or surgically sterile. 4. Female subjects of child bearing potential practicing an...

Countries:India
Unlock Eligibility Criteria